Guardian Pharmacy Services, Inc. GRDN
We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities ("ALFs"), and behavioral health facilities and group homes (collectively "BHFs"). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities ("SNFs"). Additionally, our robust suite of capabilities enables us to serve residents in all types of LTCFs. We are a trusted partner to residents, LTCFs and health plan payors because we help reduce errors in drug administration, manage and ensure adherence to drug regimens, and lower overall healthcare costs. As of December 31, 2025, our 61 pharmacies, 54 of which are full-service, served approximately 205,000 residents in approximately 8,400 LTCFs across 38 states.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.45B | $1.23B | — |
| Cost of revenue | $1.16B | $984.0M | — |
| Gross profit | $292.7M | $244.4M | — |
| SG&A | $220.0M | $307.3M | — |
| Operating income | $72.7M | -$62.9M | — |
| Interest expense | $665.0K | $3.3M | — |
| Pre-tax income | $73.4M | -$66.5M | — |
| Income tax | $24.5M | $4.6M | — |
| Net income | $49.2M | -$110.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $65.6M | $4.7M | $752.0K |
| Receivables | $101.6M | $97.2M | — |
| Inventory | $43.4M | $40.5M | — |
| Total current assets | $221.6M | $152.0M | — |
| Property, plant and equipment | $55.5M | $49.9M | — |
| Goodwill | $79.7M | $69.3M | — |
| Other intangibles | $18.5M | $14.9M | — |
| Total assets | $412.7M | $320.8M | — |
| Accounts payable | $116.2M | $102.4M | — |
| Total current liabilities | $160.7M | $144.1M | — |
| Long-term debt | $0 | $0 | — |
| Total liabilities | $194.7M | $170.8M | — |
| Retained earnings | $66.3M | $17.1M | — |
| Total equity | $217.9M | $150.0M | $59.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | $100.3M | $58.0M | — |
| Depreciation and amortisation | $22.3M | $19.8M | — |
| Stock-based compensation | $13.8M | $131.5M | — |
| Capital expenditure | $13.4M | $14.7M | — |
| Investing cash flow | -$32.2M | -$30.4M | — |
| Financing cash flow | -$7.1M | -$23.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-102172.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $1.23B | $1.45B |
| Gross profit | — | $244.4M | $292.7M |
| Net income | — | -$110.0M | $49.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 5912
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CVS | CVS HEALTH Corp | $119.55B | 67.2x | 7.8% |
| PETS | PETMED EXPRESS INC | $26.4M | — | -21.1% |
| YI | 111, Inc. | — | — | -9.0% |
| RDGT | Ridgetech Inc. | — | — | 10.2% |